TheraRadar
Data updated: May 26, 2026

FML FORTE (fluorometholone)

Corticosteroid Hormone Receptor Agonists
Ophthalmology Approved 1986-04-23

FML FORTE is indicated for the treatment of Inflammation of the palpebral conjunctiva; Inflammation of the bulbar conjunctiva; Inflammation of the cornea; Inflammation of the anterior segment of the globe.

Source: FDA Label • AbbVie
1
Indication
--
Phase 3 Trials
40
Years on Market

Details

Status
Prescription
First Approved
1986-04-23
Routes
OPHTHALMIC
Dosage Forms
SUSPENSION/DROPS

Companies

Active Ingredient: FLUOROMETHOLONE

FML FORTE Approval History

1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
25 FDA actions from 1986 to 2025
Feb 2025 SUPPL
Mfg · Manufacturing (CMC)
Feb 2013 SUPPL
Label · Labeling
Jan 2006 SUPPL
Mfg · Manufacturing (CMC)

What FML FORTE Treats

4 indications

FML FORTE is approved for 4 conditions since its original approval in 1986. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Inflammation of the palpebral conjunctiva
  • Inflammation of the bulbar conjunctiva
  • Inflammation of the cornea
  • Inflammation of the anterior segment of the globe
Source: FDA Label

FML FORTE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to FML FORTE

3 of 4

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

FLAREX
FLUOROMETHOLONE ACETATE
1 shared
HARROW EYE
Shared indications:
Inflammation of the Cornea
FLUOROMETHOLONE
FLUOROMETHOLONE
1 shared
DIFGEN PHARMS
Shared indications:
Inflammation of the cornea
OMNIPRED
PREDNISOLONE ACETATE
1 shared
Novartis
Shared indications:
Inflammation of the Cornea
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT01448213 results posted 2011-0329 Ph 2 completed Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

FML FORTE FDA Label Details

Indications & Usage

FDA Label (PDF)

FML FORTE is indicated for the treatment of Inflammation of the palpebral conjunctiva; Inflammation of the bulbar conjunctiva; Inflammation of the cornea; Inflammation of the anterior segment of the globe.

Track FML FORTE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.